文献

J-GLOBAL ID：201802263411971210   整理番号：18A1496091

オマリズマブ治療中のTh1関連疾患発症:重症喘息の2症例

Th1-related disease development during omalizumab treatment: Two cases with severe asthma

著者 (14件)： Hayashi Hiroaki (Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital) ,  Hayashi Hiroaki (Department of Respiratory Medicine, Nagoya University Graduate School of Medicine) ,  Fukutomi Yuma (Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital) ,  Mitsui Chihiro (Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital) ,  Watai Kentaro (Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital) ,  Tomita Yasuhiro (Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital) ,  Tomita Yasuhiro (Department of Respiratory Medicine, Nagoya University Graduate School of Medicine) ,  Kamide Yosuke (Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital) ,  Sekiya Kiyoshi (Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital) ,  Tsuburai Takahiro (Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital) ,  Horita Ayako (Department of Pathology, Sagamihara National Hospital) ,  Saito Ikuo (Department of Pathology, Sagamihara National Hospital) ,  Hasegawa Yoshinori (Department of Respiratory Medicine, Nagoya University Graduate School of Medicine) ,  Taniguchi Masami (Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital)
資料名： Allergology International  (Allergology International)
巻： 67  号： 3  ページ： 405-407(J-STAGE)  発行年： 2018年 
JST資料番号： L6446A  ISSN： 1323-8930  資料種別： 逐次刊行物 (A)
記事区分： 短報  発行国： 日本 (JPN)  言語： 英語 (EN)

抄録/ポイント： ・重症の喘息のオマリズマブによる治療の際にTh1関連疾患であ...

シソーラス用語： *モノクローナル抗体 ,...
準シソーラス用語： *オマリズマブ ,...

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=18A1496091&from=J-GLOBAL&jstjournalNo=L6446A") }}

分類 (1件)： 呼吸・呼吸器作用薬の臨床への応用  (GW08020U)

引用文献 (10件)：

• 1. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388-95.
• 2. Schroeder JT, Bieneman AP, Chichester KL, Hamilton RG, Xiao H, Saini SS, et al. Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol 2010;125:896-901. e6.
• 3. Djukanovic R, Wilson SJ, Kraft M, Jarjour NN, Steel M, Chung KF, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004;170:583-93.
• 4. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90.
• 5. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16.

タイトルに関連する用語 (7件)： オマリズマブ ,  治療 ,  Th1 ,  疾患 ,  発症 ,  重症喘息 ,  症例